Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.71 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CCR2 | P41597 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11786426 | 0.87 | ADRA1D (0.66) | SLC6A4ADRA1DDRD2CCR2 | |
| Hydrochloric Acid SCHEMBL11784755 | 0.86 | ADRA1D (0.67) | SLC6A4ADRA1DDRD2CCR2 | |
| Hydrochloric Acid SCHEMBL7259157 | 0.86 | ADRA1D (0.90) | SLC6A4ADRA1D | |
| SCHEMBL5705230 | 0.85 | SLC6A4 (0.90) | SLC6A4ADRA1D | |
| SCHEMBL31295331 | 0.85 | CYP2D6 (0.64) | SLC6A4ADRA1DCCR2 | |
| SCHEMBL14306777 | 0.85 | ADRA1D (0.80) | SLC6A4ADRA1D | |
| SCHEMBL3380974 | 0.84 | SLC6A4 (0.97) | SLC6A4ADRA1D | |
| SCHEMBL11788127 | 0.84 | CCR2 (0.72) | SLC6A4ADRA1DDRD2CCR2 | |
| SCHEMBL11784971 | 0.84 | DRD2 (0.70) | ADRA1DDRD2 | |
| SCHEMBL31295230 | 0.83 | CYP2D6 (0.59) | SLC6A4ADRA1DCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052384-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | US | claimed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | claimed |
| EP-1907860-B1 | MASS LABELS | ELECTROPHORETICS LTD (GB) | 2010-11-17 | — | — | EP | disclosed |
| US-20060052384-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| EP-1539158-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| WO-2004006922-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | SLC6A4 2034/4885ADRA1D 306/4885DRD2 1008/4885 |
| US-20060052384-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | LDLR, NR1H2, NR1H3 | SLC6A4 2990/4885ADRA1D 147/4885DRD2 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.